Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer

This study evaluated the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetic profile, and preliminary antitumor activity of QLNC120, an inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), in HER2 overexpressing advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tongtong, Li, Qing, Chen, Shanshan, Luo, Yang, Fan, Ying, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482694/
https://www.ncbi.nlm.nih.gov/pubmed/27902470
http://dx.doi.org/10.18632/oncotarget.13581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482694/
https://www.ncbi.nlm.nih.gov/pubmed/27902470
http://dx.doi.org/10.18632/oncotarget.13581

Ejemplares similares